Literature DB >> 11571786

Opioid system diversity in developing neurons, astroglia, and oligodendroglia in the subventricular zone and striatum: impact on gliogenesis in vivo.

A Stiene-Martin1, P E Knapp, K Martin, J A Gurwell, S Ryan, S R Thornton, F L Smith, K F Hauser.   

Abstract

Accumulating evidence, obtained largely in vitro, indicates that opioids regulate the genesis of neurons and glia and their precursors in the nervous system. Despite this evidence, few studies have assessed opioid receptor expression in identified cells within germinal zones or examined opioid effects on gliogenesis in vivo. To address this question, the role of opioids was explored in the subventricular zone (SVZ) and/or striatum of 2-5-day-old and/or adult ICR mice. The results showed that subpopulations of neurons, astrocytes, and oligodendrocytes in the SVZ and striatum differentially express mu-, delta-, and/or kappa-receptor immunoreactivity in a cell type-specific and developmentally regulated manner. In addition, DNA synthesis was assessed by examining 5-bromo-2'-deoxyuridine (BrdU) incorporation into glial and nonglial precursors. Morphine (a preferential mu-agonist) significantly decreased the number of BrdU-labeled GFAP(+) cells compared with controls or mice co-treated with naltrexone plus morphine. Alternatively, in S100beta(+) cells, morphine did not significantly decrease BrdU incorporation; however, significant differences were noted between mice treated with morphine and those treated with morphine plus naltrexone. Most cells were GFAP(-)/S100beta(-). When BrdU incorporation was assessed within the total population (glia and nonglia), morphine had no net effect, but naltrexone alone markedly increased BrdU incorporation. This finding suggests that DNA synthesis in GFAP(-)/S100beta(-) cells is tonically suppressed by endogenous opioids. Assuming that S100beta and GFAP, respectively, distinguish among younger and older astroglia, this implies that astroglial replication becomes increasingly sensitive to morphine during maturation, and suggests that opioids differentially regulate the development of distinct subpopulations of glia and glial precursors. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571786      PMCID: PMC4303466     

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  65 in total

1.  Mitogenic signalling by delta opioid receptors expressed in rat-1 fibroblasts involves activation of the p70s6k/p85s6k S6 kinase.

Authors:  M A Wilson; A R Burt; G Milligan; N G Anderson
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  kappa-opioid receptor expression defines a phenotypically distinct subpopulation of astroglia: relationship to Ca2+ mobilization, development, and the antiproliferative effect of opioids.

Authors:  J A Gurwell; M J Duncan; K Maderspach; A Stiene-Martin; R P Elde; K F Hauser
Journal:  Brain Res       Date:  1996-10-21       Impact factor: 3.252

3.  Pharmacological properties of a proenkephalin A-derived opioid peptide: BAM 18.

Authors:  D E Hurlbut; C J Evans; J D Barchas; F M Leslie
Journal:  Eur J Pharmacol       Date:  1987-06-26       Impact factor: 4.432

4.  Glial growth is regulated by agonists selective for multiple opioid receptor types in vitro.

Authors:  A Stiene-Martin; K F Hauser
Journal:  J Neurosci Res       Date:  1991-08       Impact factor: 4.164

5.  Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord.

Authors:  U Arvidsson; M Riedl; S Chakrabarti; J H Lee; A H Nakano; R J Dado; H H Loh; P Y Law; M W Wessendorf; R Elde
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

6.  Expression of glutamate transporters in rat optic nerve oligodendrocytes.

Authors:  M Domercq; M V Sánchez-Gómez; P Areso; C Matute
Journal:  Eur J Neurosci       Date:  1999-07       Impact factor: 3.386

7.  Multiple and novel specificities of monoclonal antibodies O1, O4, and R-mAb used in the analysis of oligodendrocyte development.

Authors:  R Bansal; A E Warrington; A L Gard; B Ranscht; S E Pfeiffer
Journal:  J Neurosci Res       Date:  1989-12       Impact factor: 4.164

8.  Endogenous opioid systems and the regulation of dendritic growth and spine formation.

Authors:  K F Hauser; P J McLaughlin; I S Zagon
Journal:  J Comp Neurol       Date:  1989-03-01       Impact factor: 3.215

9.  Regulation of kappa-opioid receptor mRNA level by cyclic AMP and growth factors in cultured rat glial cells.

Authors:  P Tryoen-Toth; C Gavériaux-Ruff; K Maderspach; G Labourdette
Journal:  Brain Res Mol Brain Res       Date:  1998-03-30

10.  Identification and differential regional expression of KOR-3/ORL-1 gene splice variants in mouse brain.

Authors:  Y X Pan; J Xu; B L Wan; A Zuckerman; G W Pasternak
Journal:  FEBS Lett       Date:  1998-09-11       Impact factor: 4.124

View more
  45 in total

Review 1.  Selective vulnerability of cerebellar granule neuroblasts and their progeny to drugs with abuse liability.

Authors:  Kurt F Hauser; Valeriya K Khurdayan; Robin J Goody; Avindra Nath; Alois Saria; James R Pauly
Journal:  Cerebellum       Date:  2003       Impact factor: 3.847

2.  CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates.

Authors:  Nazira El-Hage; Guanghan Wu; Jayakrishna Ambati; Annadora J Bruce-Keller; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmunol       Date:  2006-07-10       Impact factor: 3.478

Review 3.  HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse.

Authors:  Kurt F Hauser; Nazira El-Hage; Anne Stiene-Martin; William F Maragos; Avindra Nath; Yuri Persidsky; David J Volsky; Pamela E Knapp
Journal:  J Neurochem       Date:  2006-12-01       Impact factor: 5.372

4.  HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines.

Authors:  Nazira El-Hage; Guanghan Wu; Juan Wang; Jayakrishna Ambati; Pamela E Knapp; Janelle L Reed; Annadora J Bruce-Keller; Kurt F Hauser
Journal:  Glia       Date:  2006-01-15       Impact factor: 7.452

5.  Absence of μ opioid receptor mRNA expression in astrocytes and microglia of rat spinal cord.

Authors:  Sheng-Chin Kao; Xiuli Zhao; Chun-Yi Lee; Fidelis E Atianjoh; Estelle B Gauda; Myron Yaster; Yuan-Xiang Tao
Journal:  Neuroreport       Date:  2012-04-18       Impact factor: 1.837

6.  Validation of a preclinical spinal safety model: effects of intrathecal morphine in the neonatal rat.

Authors:  B David Westin; Suellen M Walker; Ronald Deumens; Marjorie Grafe; Tony L Yaksh
Journal:  Anesthesiology       Date:  2010-07       Impact factor: 7.892

7.  Glial-restricted precursors: patterns of expression of opioid receptors and relationship to human immunodeficiency virus-1 Tat and morphine susceptibility in vitro.

Authors:  S K Buch; V K Khurdayan; S E Lutz; P E Knapp; N El-Hage; K F Hauser
Journal:  Neuroscience       Date:  2007-05-02       Impact factor: 3.590

8.  CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat-exposed mice.

Authors:  Nazira El-Hage; Annadora J Bruce-Keller; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2008-09-25       Impact factor: 4.147

9.  Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.

Authors:  Jianren Mao; Backil Sung; Ru-Rong Ji; Grewo Lim
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 10.  Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.

Authors:  Kurt F Hauser; Pamela E Knapp
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.